CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers

Metastatic or recurrent colorectal cancer (CRC) patients require systemic chemotherapy, but the therapeutic options of targeted agents remain limited. CRC patients with KRAS or BRAF gene mutations exhibit a worse prognosis and are resistant to anti-EGFR treatment. Previous studies have shown that th...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2021-05, Vol.40 (18), p.3287-3302
Hauptverfasser:	Jung, Hae Rim, Oh, Yumi, Na, Deukchae, Min, Seoyeon, Kang, Jinjoo, Jang, Dongjun, Shin, Seungjae, Kim, Jiwon, Lee, Sang Eun, Jeong, Eui Man, An, Joon Yong, Sung, Chang Ohk, Lee, Won-Suk, Lee, Charles, Cho, Sung-Yup
Format:	Artikel
Sprache:	eng
Schlagworte:	13/2 13/31 13/51 13/89 38/39 38/47 38/77 42/109 45/15 631/67/1059/602 631/67/1504/1885 64/60 Apoptosis Bcl-2 protein Bcl-x protein Cell activation Cell Biology Cell death Chemotherapy Colorectal cancer Colorectal carcinoma CRISPR Epidermal growth factor receptors Gene silencing Genomes Human Genetics Internal Medicine K-Ras protein Mcl-1 protein Medicine Medicine & Public Health Metastases Mutation Oncology Patients Therapeutic targets Wnt protein Xenografts β-Catenin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!